Eden Innovations reports robust growth in EdenCrete®Pz7 sales, driven by expanded orders from Holcim Ecuador and the USA, alongside strategic US property sales aimed at debt reduction and operational efficiency.
- Holcim Ecuador doubles annual EdenCrete®Pz7 demand estimate with second large order
- Holcim USA rolls out EdenCrete®Pz7 in multiple plants and secures major multi-storey project
- Eden US doubles EdenCrete®Pz7 production capacity to meet rising global demand
- OptiBlend® sales mixed quarterly but up 32% year-to-date amid growing global enquiries
- US property sales progressing to reduce debt and operating costs, targeting positive cash flow
EdenCrete®Pz7 Sales Momentum Accelerates
Eden Innovations Ltd has reported a significant uplift in sales of its flagship concrete additive, EdenCrete®Pz7, particularly through expanded orders from Holcim Group subsidiaries in Ecuador and the United States. Holcim Ecuador placed a second order valued at approximately AUD 352,358 during the March quarter, doubling its initial annual demand forecast to around USD 920,000 (AUD 1.4 million). This surge reflects strong market acceptance since the product’s introduction in mid-2024.
Meanwhile, Holcim USA is actively rolling out EdenCrete®Pz7 across multiple concrete plants in Colorado, with initial orders supporting a large multi-storey construction project requiring 25,000 cubic yards of concrete. The company is also supplying bulk storage and dispensing equipment to additional Holcim plants, signaling growing integration of EdenCrete®Pz7 into Holcim’s commercial mixes.
Scaling Production to Match Demand
To support this rapid uptake, Eden US has doubled its production capacity for EdenCrete®Pz7 and secured increased raw material supplies. The company now has the capability to produce approximately USD 5 million (AUD 7.8 million) annually, with flexibility to expand further as global demand intensifies. This capacity boost is timely given ongoing trials and interest from Holcim operations in Canada, Mexico, the UK, and India.
India remains a key growth market, with several ready-mix and precast concrete manufacturers conducting promising trials of EdenCrete®Pz7, including the Central Road Research Institute’s evaluation for infrastructure applications. The Indian highway network’s rapid expansion underscores the potential scale for EdenCrete®Pz7 adoption in one of the world’s largest and fastest-growing concrete markets.
OptiBlend® Sales Show Mixed but Positive Trends
While Eden’s OptiBlend® Dual Fuel System experienced a 22% sales decline in the quarter to AUD 210,000, year-to-date sales have increased by 32% to AUD 860,000. The company continues to receive substantial enquiries and quotations globally, including for critical power generation applications in the US, India, Africa, and the Middle East. Current quotations stand at approximately USD 5.9 million (AUD 9.24 million), reflecting sustained market interest.
Strategic US Property Sales to Strengthen Financial Position
Eden is progressing the conditional sale of its 65.58-acre industrial property in Augusta, Georgia, with the purchaser extending inspection periods multiple times and paying extension fees totaling USD 250,000. The company is optimistic about closing this sale in the coming months. Concurrently, Eden has listed a second property in Littleton, Colorado, valued at USD 2.6 million, with several interested buyers.
Proceeds from these sales are expected to fully repay the secured loan from iBorrow LP, significantly reduce operating costs by approximately USD 864,000 (AUD 1.3 million) annually, and position Eden US for positive cash flow. The company will retain its Denver facility to continue production and administration activities.
Refinancing and Corporate Developments
In March 2025, Eden refinanced its loan previously owed to Noble Energy Pty Ltd by securing identical terms loans from entities controlled by directors Gregory and Douglas Solomon. These unsecured loans carry a 9.97% interest rate and provide working capital flexibility without materially altering the company’s financial obligations.
Payments to related parties during the quarter included consulting fees for Dr Allan Godsk Larsen, Eden’s Chief Scientist and International Business Manager, and management fees related to the Solomon directors.
Overall, Eden Innovations reported a 19% increase in quarterly sales to AUD 710,000, driven by a 52% rise in EdenCrete® products, while OptiBlend® sales declined 22% for the quarter but remain up 32% year-to-date. The company’s cash position improved slightly to AUD 897,000 at quarter-end, supported by financing activities and ongoing operational improvements.
Bottom Line?
Eden Innovations’ expanding EdenCrete® footprint and strategic asset sales set the stage for a potential cash flow turnaround, but execution risks remain.
Questions in the middle?
- Will Eden successfully close its US property sales soon enough to sustain working capital needs?
- How quickly can Eden scale EdenCrete®Pz7 production beyond current doubled capacity if global demand accelerates?
- What impact will ongoing trials in India and other markets have on EdenCrete®Pz7’s long-term revenue growth?